Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $120M oversubscribed (Nov 2025) with Merck & Co. as new equity investor. $321M total. CloakLink ADC technology reduces hydrophobicity and toxicity. Two Phase 1b solid tumor trials active.
Solve Therapeutics develops antibody-drug conjugates (ADCs) using its proprietary CloakLink technology — which reduces the hydrophobicity and systemic toxicity that are the two primary causes of ADC clinical failure. The company raised $120 million in an oversubscribed financing round in November 2025, with Merck & Co. making a direct equity investment (rather than a typical licensing deal), bringing total funding to $321 million. Two ADC programs (SLV-154 and SLV-324) are in active Phase 1b trials in solid tumor patients.
SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.